Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix +/- Add-Back Therapy in Healthy Women
NCT04978688Phase 1Completed
- Sponsor
- Myovant Sciences
- Start
- Jun 2016
- Primary completion
- Sep 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of relugolix in Uterine Fibroids (UF) and endometriosis (2 arms), sponsored by Myovant Sciences. Primary endpoints: Area Under The Concentration-Time Curve From Time Zero To Hour 24, Maximum Concentration at Week 6 and 1 more. Started Jun 2016; status: completed.
02
Drugs
relugolix
03
Conditions
Uterine Fibroids (UF)endometriosis
Beyond the preview
Go deeper on NCT04978688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978688.